Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Payables (2018 - 2025)

10x Genomics' Payables history spans 8 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, Payables fell 1.36% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $12.7 million, down 1.36%, while the annual FY2025 figure was $12.7 million, 1.36% down from the prior year.
  • Payables for Q4 2025 was $12.7 million at 10x Genomics, down from $18.1 million in the prior quarter.
  • Across five years, Payables topped out at $29.3 million in Q1 2023 and bottomed at $10.1 million in Q1 2025.
  • The 5-year median for Payables is $18.5 million (2023), against an average of $19.0 million.
  • The largest annual shift saw Payables surged 268.46% in 2021 before it tumbled 50.2% in 2025.
  • A 5-year view of Payables shows it stood at $17.4 million in 2021, then increased by 24.48% to $21.6 million in 2022, then dropped by 27.14% to $15.7 million in 2023, then fell by 17.98% to $12.9 million in 2024, then decreased by 1.36% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Payables are $12.7 million (Q4 2025), $18.1 million (Q3 2025), and $15.9 million (Q2 2025).